[ANMCO Position paper: Prognostic and therapeutic relevance of non-obstructive coronary atherosclerosis]

Giancarlo Casolo, Domenico Gabrielli, Furio Colivicchi

  • 1U.O.C. Cardiologia-UTIC, Ospedali di Città di Castello e Gubbio - Gualdo Tadino Azienda USL Umbria 1, Perugia.

Giornale Italiano Di Cardiologia (2006)
|August 31, 2021
PubMed

Insights

Non-obstructive coronary artery disease (NobsCAD) is distinct from healthy arteries and requires specific preventive strategies. Identifying NobsCAD through angiography improves patient prognosis beyond traditional risk factors.

Area of Science:

  • Cardiovascular Medicine
  • Radiology
  • Preventive Cardiology

Background:

  • Atherosclerosis commonly affects coronary arteries but may not cause significant narrowing.
  • Non-obstructive coronary artery disease (NobsCAD) is a distinct entity with prognostic implications.
  • Distinguishing NobsCAD from the absence of disease is crucial for patient management.

Purpose of the Study:

  • To emphasize the importance of detecting and reporting NobsCAD.
  • To highlight the prognostic value of NobsCAD.
  • To advocate for individualized treatment strategies based on NobsCAD assessment.

Main Methods:

  • Coronary angiography (invasive and non-invasive) as a diagnostic tool.
  • Assessment of disease severity and extent.
  • Integration of clinical condition and cardiovascular risk factors.

Main Results:

  • NobsCAD carries specific prognostic value, differing from smooth coronary arteries.
  • Individualized preventive measures are prompted by NobsCAD detection.
  • Treatment tailored to NobsCAD extent offers prognostic benefits.

Conclusions:

  • NobsCAD should not be confused with or ignored as trivial.
  • Accurate reporting of NobsCAD is essential for patient care.
  • Prognostic benefits are enhanced by considering NobsCAD in treatment decisions.

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
513
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
70
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
96
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
71
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
87
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
48